{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:11:23Z","timestamp":1779210683757,"version":"3.51.4"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Macao Science and Technology Development Fund","doi-asserted-by":"crossref","award":["FDCT0148\/2022\/A3 and 0019\/2024\/RIA1"],"award-info":[{"award-number":["FDCT0148\/2022\/A3 and 0019\/2024\/RIA1"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01795-6","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:45:48Z","timestamp":1775544348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immuno-cytotoxic convergence: integrating antibody\u2012drug conjugates and immunofusion proteins to overcome resistance in gastrointestinal cancers"],"prefix":"10.1186","volume":"19","author":[{"given":"Shenghong","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangnan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"3","key":"1795_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1795_CR2","doi-asserted-by":"publisher","first-page":"e214708","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.4708.","journal-title":"JAMA Netw Open"},{"issue":"7404","key":"1795_CR3","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532\u20136. https:\/\/doi.org\/10.1038\/nature11156.","journal-title":"Nature"},{"issue":"10","key":"1795_CR4","doi-asserted-by":"publisher","first-page":"100865","DOI":"10.1016\/j.modpat.2025.100865","volume":"38","author":"S Noguchi","year":"2025","unstructured":"Noguchi S, Yamamoto T, Nakanishi Y, et al. Prognostic significance of desmoplastic reaction classification and its association with stromal biomarkers in pancreatic ductal adenocarcinoma. Mod Pathol: Off J U S Can Acad Pathol Inc. 2025;38(10):100865. https:\/\/doi.org\/10.1016\/j.modpat.2025.100865.","journal-title":"Mod Pathol: Off J U S Can Acad Pathol Inc"},{"issue":"25","key":"1795_CR5","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2004413.","journal-title":"N Engl J Med"},{"key":"1795_CR6","doi-asserted-by":"publisher","first-page":"103404","DOI":"10.1016\/j.eclinm.2025.103404","volume":"87","author":"Z Peng","year":"2025","unstructured":"Peng Z, Chen P, Lu J, et al. Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced\/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): Results from a single-arm, multicenter, phase 2 trial. EClinicalMedicine. 2025;87:103404. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103404.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"1795_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","volume":"187","author":"Y Shapir Itai","year":"2024","unstructured":"Shapir Itai Y, Barboy O, Salomon R, et al. Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell. 2024;187(2):375\u2013e38918. https:\/\/doi.org\/10.1016\/j.cell.2023.12.011.","journal-title":"Cell"},{"issue":"3","key":"1795_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/neuonc\/noad205","volume":"26","author":"S Coy","year":"2024","unstructured":"Coy S, Lee JS, Chan SJ, et al. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. Neuro-oncol. 2024;26(3):458\u201372. https:\/\/doi.org\/10.1093\/neuonc\/noad205.","journal-title":"Neuro-oncol"},{"issue":"12","key":"1795_CR9","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20(12):2329\u201340. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0206.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1795_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","volume":"22","author":"A Kopp","year":"2023","unstructured":"Kopp A, Hofsess S, Cardillo TM, Govindan SV, Donnell J, Thurber GM. Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release. Mol Cancer Ther. 2023;22(1):102\u201311. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0375.","journal-title":"Mol Cancer Ther"},{"issue":"Pt 2","key":"1795_CR11","doi-asserted-by":"publisher","first-page":"117188","DOI":"10.1016\/j.bcp.2025.117188","volume":"242","author":"GM Mendes","year":"2025","unstructured":"Mendes GM, de Munshani M, Wachtler S. Monomethyl auristatin E and paclitaxel use different mechanisms to alter intracellular calcium signaling. Biochem Pharmacol. 2025;242(Pt 2):117188. https:\/\/doi.org\/10.1016\/j.bcp.2025.117188.","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"1795_CR12","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-10-0644","volume":"9","author":"M Lopus","year":"2010","unstructured":"Lopus M, Oroudjev E, Wilson L, et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther. 2010;9(10):2689\u201399. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0644.","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"1795_CR13","doi-asserted-by":"publisher","first-page":"e2306309","DOI":"10.1002\/advs.202306309","volume":"11","author":"Y Guo","year":"2024","unstructured":"Guo Y, Shen Z, Zhao W, et al. Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors. Adv Sci (Weinh Baden-Wurtt Ger). 2024;11(13):e2306309. https:\/\/doi.org\/10.1002\/advs.202306309.","journal-title":"Adv Sci (Weinh Baden-Wurtt Ger)"},{"issue":"1","key":"1795_CR14","doi-asserted-by":"publisher","first-page":"9650","DOI":"10.1038\/s41467-025-61858-z","volume":"16","author":"F Birocchi","year":"2025","unstructured":"Birocchi F, Almazan AJ, Parker A, et al. On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models. Nat Commun. 2025;16(1):9650. https:\/\/doi.org\/10.1038\/s41467-025-61858-z.","journal-title":"Nat Commun"},{"key":"1795_CR15","unstructured":"DESTINY-CRC02 trial results at ESMO. 2025: trastuzumab deruxtecan consolidates role in HER2-positive mCRC - OncoDaily. October 19, 2025. Accessed December 3, 2025. https:\/\/oncodaily.com\/oncolibrary\/destiny-crc02-trial-for-mcrc-at-esmo2025"},{"issue":"5","key":"1795_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 2017;18(5):640\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(17)30111-0.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1795_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72(2):165\u201382. https:\/\/doi.org\/10.3322\/caac.21705.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1795_CR18","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3390\/cancers12030670","volume":"12","author":"M Nadal-Serrano","year":"2020","unstructured":"Nadal-Serrano M, Morancho B, Escriv\u00e1-de-Roman\u00ed S, et al. The second generation antibody-drug conjugate SYD985 overcomes resistances to T-DM1. Cancers. 2020;12(3):670. https:\/\/doi.org\/10.3390\/cancers12030670.","journal-title":"Cancers"},{"issue":"7","key":"1795_CR19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41571-023-00779-6","volume":"20","author":"P Sidaway","year":"2023","unstructured":"Sidaway P. T-DXd is effective after T-DM1. Nat Rev Clin Oncol. 2023;20(7):426. https:\/\/doi.org\/10.1038\/s41571-023-00779-6.","journal-title":"Nat Rev Clin Oncol"},{"issue":"29","key":"1795_CR20","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1200\/JCO.23.02044","volume":"42","author":"H Yao","year":"2024","unstructured":"Yao H, Yan M, Tong Z, et al. Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2-directed antibody-drug conjugate, in human epidermal growth factor receptor 2-expressing or mutated advanced solid tumors: a global phase I trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2024;42(29):3453\u201365. https:\/\/doi.org\/10.1200\/JCO.23.02044.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"1","key":"1795_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41420-025-02652-0","volume":"11","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Du J, Cui X, Ling Y, Tang C. Development of a bispecific CDH17-GUCY2C ADC bearing the ferroptosis inducer RSL3 for the treatment of colorectal cancer. Cell Death Discovery. 2025;11(1):347. https:\/\/doi.org\/10.1038\/s41420-025-02652-0.","journal-title":"Cell Death Discovery"},{"issue":"1","key":"1795_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-025-01720-3","volume":"18","author":"HN Tan","year":"2025","unstructured":"Tan HN, Morcillo MA, Lopez J, et al. Treatment-related adverse events of antibody drug-conjugates in clinical trials. J Hematol Oncol. 2025;18(1):71. https:\/\/doi.org\/10.1186\/s13045-025-01720-3.","journal-title":"J Hematol Oncol"},{"issue":"39","key":"1795_CR23","doi-asserted-by":"publisher","first-page":"e2516951122","DOI":"10.1073\/pnas.2516951122","volume":"122","author":"Y Su","year":"2025","unstructured":"Su Y, Thelen A, Wirth LV, et al. A TGF-\u03b2R\/IL-2R immunomodulatory fusion protein transforms immunosuppression into T cell activation to enhance adoptive T cell therapy. Proc Natl Acad Sci U S A. 2025;122(39):e2516951122. https:\/\/doi.org\/10.1073\/pnas.2516951122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"1795_CR24","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1158\/1078-0432.CCR-23-3567","volume":"30","author":"N Steeghs","year":"2024","unstructured":"Steeghs N, Gomez-Roca C, Rohrberg KS, et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity from a phase I study of simlukafusp alfa (FAP-IL2v) in advanced\/metastatic solid tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2024;30(13):2693\u2013701. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3567.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"1","key":"1795_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12964-023-01151-y","volume":"21","author":"Z Kalaei","year":"2023","unstructured":"Kalaei Z, Manafi-Farid R, Rashidi B, et al. The prognostic and therapeutic value and clinical implications of fibroblast activation protein-\u03b1 as a novel biomarker in colorectal cancer. Cell Commun Signal: CCS. 2023;21(1):139. https:\/\/doi.org\/10.1186\/s12964-023-01151-y.","journal-title":"Cell Commun Signal: CCS"},{"issue":"5","key":"1795_CR26","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ccell.2023.04.001","volume":"41","author":"M Piper","year":"2023","unstructured":"Piper M, Hoen M, Darragh LB, et al. Simultaneous targeting of PD-1 and IL-2R\u03b2\u03b3 with radiation therapy inhibits pancreatic cancer growth and metastasis. Cancer Cell. 2023;41(5):950\u2013e9696. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.001.","journal-title":"Cancer Cell"},{"issue":"1","key":"1795_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ymthe.2022.08.016","volume":"31","author":"W Shi","year":"2023","unstructured":"Shi W, Lv L, Liu N, et al. A novel anti-PD-L1\/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity. Mol Ther: J Am Soc Gene Ther. 2023;31(1):66\u201377. https:\/\/doi.org\/10.1016\/j.ymthe.2022.08.016.","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"issue":"8","key":"1795_CR28","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2326-6066.CIR-23-0636","volume":"12","author":"NK Mehta","year":"2024","unstructured":"Mehta NK, Rakhra K, Meetze KA, et al. CLN-617 retains IL2 and IL12 in injected tumors to drive robust and systemic immune-mediated antitumor activity. Cancer Immunol Res. 2024;12(8):1022\u201338. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-0636.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1795_CR29","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","volume":"15","author":"NH Segal","year":"2024","unstructured":"Segal NH, Melero I, Moreno V, et al. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: Results of two multi-institutional phase 1 trials. Nat Commun. 2024;15(1):4091. https:\/\/doi.org\/10.1038\/s41467-024-48479-8.","journal-title":"Nat Commun"},{"issue":"8","key":"1795_CR30","doi-asserted-by":"publisher","first-page":"e011857","DOI":"10.1136\/jitc-2025-011857","volume":"13","author":"M Gaspar","year":"2025","unstructured":"Gaspar M, Natoli M, Castan L, et al. An affinity-modulated T cell engager targeting claudin 18.2 shows potent anti-tumor activity with limited cytokine release. J ImmunoTher Cancer. 2025;13(8):e011857. https:\/\/doi.org\/10.1136\/jitc-2025-011857.","journal-title":"J ImmunoTher Cancer"},{"issue":"11","key":"1795_CR31","doi-asserted-by":"publisher","first-page":"e013001","DOI":"10.1136\/jitc-2025-013001","volume":"13","author":"X Kang","year":"2025","unstructured":"Kang X, Qian P, Han Y, et al. A bispecific antibody targeting PD-L1\/TNFR2 increases tumor targeting and enhances antitumor efficacy in colorectal cancer. J ImmunoTher Cancer. 2025;13(11):e013001. https:\/\/doi.org\/10.1136\/jitc-2025-013001.","journal-title":"J ImmunoTher Cancer"},{"issue":"Suppl 2","key":"1795_CR32","doi-asserted-by":"publisher","first-page":"A735","DOI":"10.1136\/jitc-2021-SITC2021.706","volume":"9","author":"A Berezhnoy","year":"2021","unstructured":"Berezhnoy A, Wang H, Cai N, et al. 706\u2005conditional cytokine therapeutics for tumor-selective biological activity: preclinical characterization of a dual-masked IFN-a2b. J ImmunoTher Cancer. 2021;9(Suppl 2):A735\u2013735. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.706.","journal-title":"J ImmunoTher Cancer"},{"key":"1795_CR33","unstructured":"Theofilidis P. The Goldilocks Zone: Optimizing T Cell Engager Affinity, Kinetics and Architecture for Anti-Tumor Efficacy. Master thesis. 2025. Accessed December 13, 2025. https:\/\/studenttheses.uu.nl\/handle\/20.500.12932\/48904"},{"issue":"2","key":"1795_CR34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41423-021-00786-6","volume":"19","author":"X Zheng","year":"2022","unstructured":"Zheng X, Wu Y, Bi J, et al. The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cell Mol Immunol. 2022;19(2):192\u2013209. https:\/\/doi.org\/10.1038\/s41423-021-00786-6.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"1795_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23(4):301\u201319. https:\/\/doi.org\/10.1038\/s41573-024-00896-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1795_CR36","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1093\/oncolo\/oyac254","volume":"28","author":"A Spira","year":"2023","unstructured":"Spira A, Wertheim MS, Kim EJ, et al. Bintrafusp alfa: a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with pretreated colorectal cancer: results from a phase I trial. Oncologist. 2023;28(2):e124\u20137. https:\/\/doi.org\/10.1093\/oncolo\/oyac254.","journal-title":"Oncologist"},{"issue":"1","key":"1795_CR37","doi-asserted-by":"publisher","first-page":"e000564","DOI":"10.1136\/jitc-2020-000564","volume":"8","author":"C Yoo","year":"2020","unstructured":"Yoo C, Oh DY, Choi HJ, et al. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with pretreated biliary tract cancer. J ImmunoTher Cancer. 2020;8(1):e000564. https:\/\/doi.org\/10.1136\/jitc-2020-000564.","journal-title":"J ImmunoTher Cancer"},{"issue":"3","key":"1795_CR38","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/HEP.0000000000000965","volume":"81","author":"DY Oh","year":"2025","unstructured":"Oh DY, Ikeda M, Lee CK, et al. Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: a randomized phase 2\/3 trial. Hepatol (Baltim Md). 2025;81(3):823\u201336. https:\/\/doi.org\/10.1097\/HEP.0000000000000965.","journal-title":"Hepatol (Baltim Md)"},{"issue":"7","key":"1795_CR39","doi-asserted-by":"publisher","first-page":"e002428","DOI":"10.1136\/jitc-2021-002428","volume":"9","author":"S Jeong","year":"2021","unstructured":"Jeong S, Park E, Kim HD, et al. Novel anti-4-1BB\u00d7PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade. J ImmunoTher Cancer. 2021;9(7):e002428. https:\/\/doi.org\/10.1136\/jitc-2021-002428.","journal-title":"J ImmunoTher Cancer"},{"issue":"18","key":"1795_CR40","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.1158\/1078-0432.CCR-23-2864","volume":"30","author":"SH Jeon","year":"2024","unstructured":"Jeon SH, You G, Park J, et al. Anti-4-1BB\u00d7PDL1 bispecific antibody reinvigorates tumor-specific exhausted CD8\u2009+\u2009T cells and enhances the efficacy of anti-PD1 blockade. Clin Cancer Res: Off J Am Assoc Cancer Res. 2024;30(18):4155\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2864.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"44","key":"1795_CR41","doi-asserted-by":"publisher","first-page":"14338","DOI":"10.1039\/d5tb01381j","volume":"13","author":"X Lei","year":"2025","unstructured":"Lei X, Wang Y, Zhang X, Du S, She J. Based on multi-pathway induction of tumor immunogenic death and three-mode highly integrated strategy: a nanocomposite system loaded with irinotecan for colorectal cancer therapy. J Mater Chem B. 2025;13(44):14338\u201353. https:\/\/doi.org\/10.1039\/d5tb01381j.","journal-title":"J Mater Chem B"},{"issue":"10","key":"1795_CR42","doi-asserted-by":"publisher","first-page":"e009710","DOI":"10.1136\/jitc-2024-009710","volume":"12","author":"Y Dong","year":"2024","unstructured":"Dong Y, Zhang Z, Luan S, et al. Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses. J ImmunoTher Cancer. 2024;12(10):e009710. https:\/\/doi.org\/10.1136\/jitc-2024-009710.","journal-title":"J ImmunoTher Cancer"},{"issue":"4","key":"1795_CR43","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","volume":"14","author":"F Loganzo","year":"2015","unstructured":"Loganzo F, Tan X, Sung M, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015;14(4):952\u201363. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0862.","journal-title":"Mol Cancer Ther"},{"issue":"9742","key":"1795_CR44","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (Lond Engl). 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet (Lond Engl)"},{"issue":"1","key":"1795_CR45","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"LC Tsao","year":"2025","unstructured":"Tsao LC, Wang JS, Ma X, et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025;16(1):3167. https:\/\/doi.org\/10.1038\/s41467-025-58266-8.","journal-title":"Nat Commun"},{"issue":"7","key":"1795_CR46","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat Med. 2024;30(7):1933\u201342. https:\/\/doi.org\/10.1038\/s41591-024-02992-x.","journal-title":"Nat Med"},{"key":"1795_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.10.004","volume":"178","author":"J Xu","year":"2023","unstructured":"Xu J, Ying J, Liu R, et al. KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer. Eur J Cancer (Oxf Engl: 1990). 2023;178:1\u201312. https:\/\/doi.org\/10.1016\/j.ejca.2022.10.004.","journal-title":"Eur J Cancer (Oxf Engl: 1990)"},{"issue":"7","key":"1795_CR48","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S1470-2045(25)00287-6","volume":"26","author":"E Elimova","year":"2025","unstructured":"Elimova E, Ajani J, Burris H, et al. Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study. Lancet Oncol. 2025;26(7):847\u201359. https:\/\/doi.org\/10.1016\/S1470-2045(25)00287-6.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1795_CR49","doi-asserted-by":"publisher","first-page":"oyae238","DOI":"10.1093\/oncolo\/oyae238","volume":"30","author":"Y Kwak","year":"2025","unstructured":"Kwak Y, Kim TY, Nam SK, et al. Clinicopathologic and molecular characterization of stages II-IV gastric cancer with claudin 18.2 expression. Oncologist. 2025;30(2):oyae238. https:\/\/doi.org\/10.1093\/oncolo\/oyae238.","journal-title":"Oncologist"},{"issue":"10389","key":"1795_CR50","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial. Lancet (Lond Engl). 2023;401(10389):1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet (Lond Engl)"},{"issue":"8","key":"1795_CR51","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"issue":"2","key":"1795_CR52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, Liu FR, Wei XL, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025;26(2):227\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(24)00636-3.","journal-title":"Lancet Oncol"},{"key":"1795_CR53","doi-asserted-by":"publisher","first-page":"115808","DOI":"10.1016\/j.ejca.2025.115808","volume":"230","author":"C Bai","year":"2025","unstructured":"Bai C, Zheng Y, Sun M, et al. Tecotabart vedotin in claudin 18.2-positive advanced gastric\/gastroesophageal junction cancer: a bayesian phase 1\/2 clinical trial. Eur J Cancer (Oxf Engl: 1990). 2025;230:115808. https:\/\/doi.org\/10.1016\/j.ejca.2025.115808.","journal-title":"Eur J Cancer (Oxf Engl: 1990)"},{"issue":"7","key":"1795_CR54","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/cncr.31125","volume":"124","author":"JS Ross","year":"2018","unstructured":"Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124(7):1358\u201373. https:\/\/doi.org\/10.1002\/cncr.31125.","journal-title":"Cancer"},{"issue":"5","key":"1795_CR55","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/jamaoncol.2018.7229","volume":"5","author":"G Bregni","year":"2019","unstructured":"Bregni G, Sciallero S, Sobrero A. HER2 amplification and anti-EGFR sensitivity in advanced colorectal cancer. JAMA Oncol. 2019;5(5):605\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2018.7229.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1795_CR56","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","volume":"22","author":"S Siena","year":"2021","unstructured":"Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(21)00086-3.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1795_CR57","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","volume":"25","author":"K Raghav","year":"2024","unstructured":"Raghav K, Siena S, Takashima A, et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25(9):1147\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(24)00380-2.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1795_CR58","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s41416-023-02180-7","volume":"128","author":"R Moretto","year":"2023","unstructured":"Moretto R, Germani MM, Giordano M, et al. Trop-2 and nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs\u2019 development. Br J Cancer. 2023;128(7):1391\u20139. https:\/\/doi.org\/10.1038\/s41416-023-02180-7.","journal-title":"Br J Cancer"},{"issue":"29","key":"1795_CR59","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1200\/JCO.23.02767","volume":"42","author":"AD Santin","year":"2024","unstructured":"Santin AD, Corr BR, Spira A, et al. Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2024;42(29):3421\u20139. https:\/\/doi.org\/10.1200\/JCO.23.02767.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1795_CR60","doi-asserted-by":"publisher","first-page":"1624386","DOI":"10.3389\/fonc.2025.1624386","volume":"15","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen J, Wang X, et al. Efficacy and safety of sacituzumab govitecan in solid tumors: A systematic review and meta-analysis. Front Oncol. 2025;15:1624386. https:\/\/doi.org\/10.3389\/fonc.2025.1624386.","journal-title":"Front Oncol"},{"key":"1795_CR61","doi-asserted-by":"crossref","unstructured":"Abstract 6742: high-affinity human IgG1 antibody against GUCY2C for ADC development: identification, characterization, and efficacy | cancer research | american association for cancer research. Accessed December 13. 2025. https:\/\/aacrjournals.org\/cancerres\/article\/85\/8_Supplement_1\/6742\/759816","DOI":"10.1158\/1538-7445.AM2025-6742"},{"issue":"9","key":"1795_CR62","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1158\/1078-0432.CCR-19-3275","volume":"26","author":"D Mathur","year":"2020","unstructured":"Mathur D, Root AR, Bugaj-Gaweda B, et al. A novel GUCY2C-CD3 T-cell engaging bispecific construct (PF-07062119) for the treatment of gastrointestinal cancers. Clin Cancer Res: Off J Am Assoc Cancer Res. 2020;26(9):2188\u2013202. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3275.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"1795_CR63","doi-asserted-by":"publisher","unstructured":"Ozawa H, Takahashi K, Motegi T, et al. Targeting KRAS inhibitor-resistant pancreatic cancer with a MUC1-C antibody-drug conjugate. Clin Cancer Res: Off J Am Assoc Cancer Res Published online Oct. 2025;14. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-2333.","DOI":"10.1158\/1078-0432.CCR-25-2333"},{"issue":"1","key":"1795_CR64","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41467-024-46167-1","volume":"15","author":"Y Nakazawa","year":"2024","unstructured":"Nakazawa Y, Miyano M, Tsukamoto S, et al. Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models. Nat Commun. 2024;15(1):2192. https:\/\/doi.org\/10.1038\/s41467-024-46167-1.","journal-title":"Nat Commun"},{"issue":"3","key":"1795_CR65","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1158\/1535-7163.MCT-24-0444","volume":"24","author":"H Kogai","year":"2025","unstructured":"Kogai H, Tsukamoto S, Koga M, et al. Broad-spectrum efficacy of CEACAM6-targeted antibody-drug conjugate with BET protein degrader in colorectal, lung, and breast cancer mouse models. Mol Cancer Ther. 2025;24(3):392\u2013405. https:\/\/doi.org\/10.1158\/1535-7163.MCT-24-0444.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"1795_CR66","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-22-2981","volume":"29","author":"MSJ McDermott","year":"2023","unstructured":"McDermott MSJ, O\u2019Brien NA, Hoffstrom B, et al. Preclinical efficacy of the antibody-drug conjugate CLDN6-23-ADC for the treatment of CLDN6-positive solid tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2023;29(11):2131\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2981.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"1","key":"1795_CR67","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1795_CR68","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1158\/2767-9764.CRC-23-0284","volume":"3","author":"J Tabernero","year":"2023","unstructured":"Tabernero J, Bedard PL, Bang YJ, et al. Tusamitamab ravtansine in patients with advanced solid tumors: phase I study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens. Cancer Res Commun. 2023;3(8):1662\u201371. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0284.","journal-title":"Cancer Res Commun"},{"key":"1795_CR69","doi-asserted-by":"publisher","first-page":"1238667","DOI":"10.3389\/fimmu.2023.1238667","volume":"14","author":"Q Qiao","year":"2023","unstructured":"Qiao Q, Han C, Ye S, et al. The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase ib\/II single-arm clinical trial. Front Immunol. 2023;14:1238667. https:\/\/doi.org\/10.3389\/fimmu.2023.1238667.","journal-title":"Front Immunol"},{"issue":"7","key":"1795_CR70","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/15384047.2020.1743158","volume":"21","author":"L Yu","year":"2020","unstructured":"Yu L, Yang X, Huang N, et al. A novel targeted GPC3\/CD3 bispecific antibody for the treatment hepatocellular carcinoma. Cancer Biol Ther. 2020;21(7):597\u2013603. https:\/\/doi.org\/10.1080\/15384047.2020.1743158.","journal-title":"Cancer Biol Ther"},{"issue":"14","key":"1795_CR71","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1158\/0008-5472.CAN-23-0510","volume":"83","author":"Y Bei","year":"2023","unstructured":"Bei Y, He J, Dong X, et al. Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma. Cancer Res. 2023;83(14):2405\u201320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0510.","journal-title":"Cancer Res"},{"issue":"9","key":"1795_CR72","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1038\/s44321-024-00121-2","volume":"16","author":"HC Chen","year":"2024","unstructured":"Chen HC, Mueller N, Stott K, et al. Novel immunotherapeutics against LGR5 to target multiple cancer types. EMBO Mol Med. 2024;16(9):2233\u201361. https:\/\/doi.org\/10.1038\/s44321-024-00121-2.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"1795_CR73","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): Primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(23)00215-2.","journal-title":"Lancet Oncol"},{"key":"1795_CR74","doi-asserted-by":"publisher","first-page":"gutjnl","DOI":"10.1136\/gutjnl-2024-334667","volume":"30","author":"T Sheng","year":"2025","unstructured":"Sheng T, Sundar R, Srivastava S, et al. Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy. Gut Published online Oct. 2025;30:gutjnl\u20132024. https:\/\/doi.org\/10.1136\/gutjnl-2024-334667.","journal-title":"Gut Published online Oct"},{"issue":"12","key":"1795_CR75","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1056\/NEJMe2411494","volume":"391","author":"EJ Rubin","year":"2024","unstructured":"Rubin EJ, Yeku OO, Morrissey S. NEJM at ESMO - zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N Engl J Med. 2024;391(12):e26. https:\/\/doi.org\/10.1056\/NEJMe2411494.","journal-title":"N Engl J Med"},{"issue":"4","key":"1795_CR76","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1200\/JCO.22.00575","volume":"41","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2023;41(4):816\u201325. https:\/\/doi.org\/10.1200\/JCO.22.00575.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"11","key":"1795_CR77","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.3390\/biomedicines11113080","volume":"11","author":"S Balamkundu","year":"2023","unstructured":"Balamkundu S, Liu CF. Lysosomal-cleavable peptide linkers in antibody-drug conjugates. Biomedicines. 2023;11(11):3080. https:\/\/doi.org\/10.3390\/biomedicines11113080.","journal-title":"Biomedicines"},{"issue":"5","key":"1795_CR78","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1124\/dmd.119.089276","volume":"48","author":"S Sharma","year":"2020","unstructured":"Sharma S, Li Z, Bussing D, Shah DK. Evaluation of quantitative relationship between target expression and antibody-drug conjugate exposure inside cancer cells. Drug Metab Dispos: Biol Fate Chem. 2020;48(5):368\u201377. https:\/\/doi.org\/10.1124\/dmd.119.089276.","journal-title":"Drug Metab Dispos: Biol Fate Chem"},{"issue":"4","key":"1795_CR79","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.resinv.2025.05.012","volume":"63","author":"Y Murase","year":"2025","unstructured":"Murase Y, Nanjo S, Ueda T, et al. Mechanisms of resistance to antibody-drug conjugates in cancers. Respir Investig. 2025;63(4):693\u20138. https:\/\/doi.org\/10.1016\/j.resinv.2025.05.012.","journal-title":"Respir Investig"},{"issue":"7","key":"1795_CR80","doi-asserted-by":"publisher","first-page":"102213","DOI":"10.1016\/j.xcrm.2025.102213","volume":"6","author":"R Wang","year":"2025","unstructured":"Wang R, Fang P, Chen X, et al. Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor. Cell Rep Med. 2025;6(7):102213. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102213.","journal-title":"Cell Rep Med"},{"issue":"17","key":"1795_CR81","doi-asserted-by":"publisher","first-page":"18020","DOI":"10.1002\/cam4.6407","volume":"12","author":"S Byeon","year":"2023","unstructured":"Byeon S, du Toit-Thompson T, Gillson J, et al. Heterogeneous tumor microenvironment in pancreatic ductal adenocarcinoma: an emerging role of single-cell analysis. Cancer Med. 2023;12(17):18020\u201331. https:\/\/doi.org\/10.1002\/cam4.6407.","journal-title":"Cancer Med"},{"issue":"1","key":"1795_CR82","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/s42003-025-09087-4","volume":"8","author":"SY Lee","year":"2025","unstructured":"Lee SY, Lee Y. Fibroblast TGF-\u03b2 signaling defines spatial tumor ecosystems linked to immune checkpoint blockade resistance. Commun Biol. 2025;8(1):1730. https:\/\/doi.org\/10.1038\/s42003-025-09087-4.","journal-title":"Commun Biol"},{"issue":"6","key":"1795_CR83","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3390\/ijms18061331","volume":"18","author":"M \u0160mahel","year":"2017","unstructured":"\u0160mahel M. PD-1\/PD-L1 blockade therapy for tumors with downregulated MHC class I expression. Int J Mol Sci. 2017;18(6):1331. https:\/\/doi.org\/10.3390\/ijms18061331.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1795_CR84","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13148-018-0539-3","volume":"10","author":"V Sasidharan Nair","year":"2018","unstructured":"Sasidharan Nair V, Toor SM, Taha RZ, Shaath H, Elkord E. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clin Epigenet. 2018;10(1):104. https:\/\/doi.org\/10.1186\/s13148-018-0539-3.","journal-title":"Clin Epigenet"},{"issue":"9","key":"1795_CR85","doi-asserted-by":"publisher","first-page":"e2206873","DOI":"10.1002\/advs.202206873","volume":"10","author":"HC Liu","year":"2023","unstructured":"Liu HC, Davila Gonzalez D, Viswanath DI, et al. Sustained intratumoral administration of agonist CD40 antibody overcomes immunosuppressive tumor microenvironment in pancreatic cancer. Adv Sci (Weinh Baden-Wurtt Ger). 2023;10(9):e2206873. https:\/\/doi.org\/10.1002\/advs.202206873.","journal-title":"Adv Sci (Weinh Baden-Wurtt Ger)"},{"key":"1795_CR86","doi-asserted-by":"publisher","unstructured":"Fumet JD, Latour C, Nuttin L, et al. Tumor-associated macrophages produce PGE2 to promote CD8\u2009+\u2009T cell exhaustion and drive resistance to PD-L1 blockade in microsatellite stable colorectal cancer. Cancer Res Published online November. 2025;6. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-0079.","DOI":"10.1158\/0008-5472.CAN-25-0079"},{"issue":"15","key":"1795_CR87","doi-asserted-by":"publisher","first-page":"7567","DOI":"10.3390\/ijms26157567","volume":"26","author":"L Nan","year":"2025","unstructured":"Nan L, Qin Y, Huang X, et al. A bifunctional anti-PD-1\/TGF-\u03b2 fusion antibody restores antitumour immunity and remodels the tumour microenvironment. Int J Mol Sci. 2025;26(15):7567. https:\/\/doi.org\/10.3390\/ijms26157567.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1795_CR88","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1080\/15548627.2023.2300913","volume":"20","author":"X Zhang","year":"2024","unstructured":"Zhang X, Lao M, Yang H, et al. Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. Autophagy. 2024;20(6):1314\u201334. https:\/\/doi.org\/10.1080\/15548627.2023.2300913.","journal-title":"Autophagy"},{"key":"1795_CR89","doi-asserted-by":"publisher","first-page":"216985","DOI":"10.1016\/j.canlet.2024.216985","volume":"595","author":"DJ Agorku","year":"2024","unstructured":"Agorku DJ, Bosio A, Alves F, Str\u00f6bel P, Hardt O. Colorectal cancer-associated fibroblasts inhibit effector T cells via NECTIN2 signaling. Cancer Lett. 2024;595:216985. https:\/\/doi.org\/10.1016\/j.canlet.2024.216985.","journal-title":"Cancer Lett"},{"issue":"8","key":"1795_CR90","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ccell.2025.05.017","volume":"43","author":"F Huang","year":"2025","unstructured":"Huang F, Liu Z, Song Y, et al. Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma. Cancer Cell. 2025;43(8):1460\u2013e147510. https:\/\/doi.org\/10.1016\/j.ccell.2025.05.017.","journal-title":"Cancer Cell"},{"issue":"1","key":"1795_CR91","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40360-025-00877-4","volume":"26","author":"Y Shi","year":"2025","unstructured":"Shi Y, Yao K, Zhao J, Yue Y, Wu H. Gastrointestinal toxicity of antibody-drug conjugates: a pharmacovigilance study using the FAERS database. BMC Pharmacol Toxicol. 2025;26(1):50. https:\/\/doi.org\/10.1186\/s40360-025-00877-4.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"1795_CR92","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","volume":"31","author":"KK Radtke","year":"2025","unstructured":"Radtke KK, Bender BC, Li Z, et al. Clinical pharmacology of cytokine release syndrome with T-cell-engaging bispecific antibodies: current insights and drug development strategies. Clin Cancer Res: Off J Am Assoc Cancer Res. 2025;31(2):245\u201357. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2247.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"1","key":"1795_CR93","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12916-025-03913-6","volume":"23","author":"W Gao","year":"2025","unstructured":"Gao W, Yu J, Sun Y, et al. Adverse events in the nervous system associated with blinatumomab: a real-world study. BMC Med. 2025;23(1):72. https:\/\/doi.org\/10.1186\/s12916-025-03913-6.","journal-title":"BMC Med"},{"key":"1795_CR94","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.3389\/fimmu.2019.01892","volume":"10","author":"JP Bogen","year":"2019","unstructured":"Bogen JP, Hinz SC, Grzeschik J, et al. Dual function pH responsive bispecific antibodies for tumor targeting and antigen depletion in plasma. Front Immunol. 2019;10:1892. https:\/\/doi.org\/10.3389\/fimmu.2019.01892.","journal-title":"Front Immunol"},{"issue":"5","key":"1795_CR95","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s10120-025-01621-x","volume":"28","author":"M He","year":"2025","unstructured":"He M, Ji C, Li Z, et al. Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer. Gastric Cancer: Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2025;28(5):872\u201385. https:\/\/doi.org\/10.1007\/s10120-025-01621-x.","journal-title":"Gastric Cancer: Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"2","key":"1795_CR96","doi-asserted-by":"publisher","first-page":"115229","DOI":"10.1016\/j.celrep.2024.115229","volume":"44","author":"M Sibai","year":"2025","unstructured":"Sibai M, Cervilla S, Grases D, et al. The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity. Cell Rep. 2025;44(2):115229. https:\/\/doi.org\/10.1016\/j.celrep.2024.115229.","journal-title":"Cell Rep"},{"issue":"12","key":"1795_CR97","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1002\/1878-0261.70116","volume":"19","author":"M Lapin","year":"2025","unstructured":"Lapin M, Tjensvoll K, Edland KH, et al. Tumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragmentomics. Mol Oncol. 2025;19(12):3535\u201347. https:\/\/doi.org\/10.1002\/1878-0261.70116.","journal-title":"Mol Oncol"},{"key":"1795_CR98","unstructured":"Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment. Accessed December 10. 2025. https:\/\/www.merckgroup.com:443\/en\/news\/bintrafusp-topline-data-biliary-tract-cancer-16-03-2021.html"},{"issue":"3","key":"1795_CR99","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11523-025-01140-w","volume":"20","author":"G Lalli","year":"2025","unstructured":"Lalli G, Sabatucci I, Paderno M, et al. Navigating the landscape of resistance mechanisms in antibody-drug conjugates for cancer treatment. Target Oncol. 2025;20(3):419\u201330. https:\/\/doi.org\/10.1007\/s11523-025-01140-w.","journal-title":"Target Oncol"},{"issue":"4","key":"1795_CR100","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.trecan.2024.01.003","volume":"10","author":"GJ Kembuan","year":"2024","unstructured":"Kembuan GJ, Kim JY, Maus MV, Jan M. Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology. Trends Cancer. 2024;10(4):312\u201331. https:\/\/doi.org\/10.1016\/j.trecan.2024.01.003.","journal-title":"Trends Cancer"},{"issue":"1","key":"1795_CR101","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-019-0575-3","volume":"7","author":"R Gonzalez-Exposito","year":"2019","unstructured":"Gonzalez-Exposito R, Semiannikova M, Griffiths B, et al. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J ImmunoTher Cancer. 2019;7(1):101. https:\/\/doi.org\/10.1186\/s40425-019-0575-3.","journal-title":"J ImmunoTher Cancer"},{"issue":"7","key":"1795_CR102","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039\u201346. https:\/\/doi.org\/10.1111\/cas.12966.","journal-title":"Cancer Sci"},{"key":"1795_CR103","doi-asserted-by":"publisher","first-page":"175883592413094","DOI":"10.1177\/17588359241309461","volume":"17","author":"D Izzo","year":"2025","unstructured":"Izzo D, Ascione L, Guidi L, et al. Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy. Ther Adv Med Oncol. 2025;17:17588359241309461. https:\/\/doi.org\/10.1177\/17588359241309461.","journal-title":"Ther Adv Med Oncol"},{"key":"1795_CR104","doi-asserted-by":"publisher","unstructured":"Liu B, Nguyen HVT, Jiang Y, et al. Antibody-bottlebrush prodrug conjugates for targeted cancer therapy. Nat Biotechnol Published online September. 2025;9. https:\/\/doi.org\/10.1038\/s41587-025-02772-z.","DOI":"10.1038\/s41587-025-02772-z"},{"issue":"Pt 3","key":"1795_CR105","doi-asserted-by":"publisher","first-page":"148101","DOI":"10.1016\/j.ijbiomac.2025.148101","volume":"330","author":"C Li","year":"2025","unstructured":"Li C, Chen F, Wu J, et al. Antibody-DNA nanostructure conjugates exhibit inhibited effects on CT26 cells and prevent upregulation of PD-1 in the tumor microenvironment. Int J Biol Macromol. 2025;330(Pt 3):148101. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.148101.","journal-title":"Int J Biol Macromol"},{"issue":"10","key":"1795_CR106","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2967\/jnumed.124.267685","volume":"65","author":"BA Vaughn","year":"2024","unstructured":"Vaughn BA, Lee SG, Vargas DB, et al. Theranostic GPA33-pretargeted radioimmunotherapy of human colorectal carcinoma with a bivalent 177Lu-labeled radiohapten. J Nucl Med: Off Publ Soc Nucl Med. 2024;65(10):1611\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.267685.","journal-title":"J Nucl Med: Off Publ Soc Nucl Med"},{"issue":"5","key":"1795_CR107","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00259-023-06561-1","volume":"51","author":"Z Zeng","year":"2024","unstructured":"Zeng Z, Li L, Tao J, et al. [177Lu]lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models. Eur J Nucl Med Mol Imaging. 2024;51(5):1221\u201332. https:\/\/doi.org\/10.1007\/s00259-023-06561-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1795_CR108","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3892\/or.2025.9009","volume":"55","author":"H Du","year":"2026","unstructured":"Du H, Hao XF, Lin BW, et al. Comparative analysis of the efficacy and safety of antibody-drug conjugates, radionuclide-drug conjugates and their combination targeting claudin 18.2 in gastric cancer treatment. Oncol Rep. 2026;55(1):4\u201318. https:\/\/doi.org\/10.3892\/or.2025.9009.","journal-title":"Oncol Rep"},{"key":"1795_CR109","unstructured":"Oncology A. Alphamab oncology announces IND application for innovative PD-L1\/ VEGFR2 bispecific ADC JSKN027 was officially accepted by CDE. Accessed January 2, 2026. https:\/\/www.prnewswire.com\/apac\/news-releases\/alphamab-oncology-announces-ind-application-for-innovative-pd-l1-vegfr2-bispecific-adc-jskn027-was-officially-accepted-by-cde-302645335.html"},{"key":"1795_CR110","doi-asserted-by":"publisher","unstructured":"Natoli M, Rahmy S, Gar\u00e7on F, et al. 1073 AZD5863, a CLDN18.2 and CD3 binding T-cell engager, establishes a multi-faceted antitumour immune response and combines effectively with chemo-immunotherapy regimens. J ImmunoTher Cancer. 2024;12(Suppl 2). https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.1073.","DOI":"10.1136\/jitc-2024-SITC2024.1073"},{"issue":"1","key":"1795_CR111","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12967-023-04080-z","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu Y, Sun Y, Wang P, et al. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer. J Transl Med. 2023;21(1):255. https:\/\/doi.org\/10.1186\/s12967-023-04080-z.","journal-title":"J Transl Med"},{"key":"1795_CR112","doi-asserted-by":"publisher","unstructured":"Murad JP, Christian L, Rosa R, et al. Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nat Biomed Eng Published online Oct. 2025;1. https:\/\/doi.org\/10.1038\/s41551-025-01509-2.","DOI":"10.1038\/s41551-025-01509-2"},{"key":"1795_CR113","doi-asserted-by":"publisher","first-page":"118565","DOI":"10.1016\/j.biopha.2025.118565","volume":"192","author":"YL Lo","year":"2025","unstructured":"Lo YL, Lin HC, Lee Y, Chuang HY, Chou TF. TME-responsive nanoparticles co-targeting VCP, NETs, and dual immune checkpoints for immune revitalization in EGFR\/PD-L1\/CTLA-4-driven colorectal cancer. Biomed Pharmacother. 2025;192:118565. https:\/\/doi.org\/10.1016\/j.biopha.2025.118565.","journal-title":"Biomed Pharmacother"},{"key":"1795_CR114","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","volume":"68","author":"Y Wang","year":"2024","unstructured":"Wang Y, Gong J, Wang A, et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine. 2024;68:102415. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102415.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1795_CR115","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/s41598-025-86504-y","volume":"15","author":"S Dong","year":"2025","unstructured":"Dong S, Wei C, Wang X, et al. A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer. Sci Rep. 2025;15(1):2232. https:\/\/doi.org\/10.1038\/s41598-025-86504-y.","journal-title":"Sci Rep"},{"issue":"3suppl","key":"1795_CR116","doi-asserted-by":"publisher","first-page":"TPS427","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS427","volume":"42","author":"L Shen","year":"2024","unstructured":"Shen L, Ding G, Feng D, Fang J. A randomized phase II\/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy\/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer. J Clin Oncol. 2024;42(3suppl):TPS427\u2013427. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.TPS427.","journal-title":"J Clin Oncol"},{"issue":"4suppl","key":"1795_CR117","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1200\/JCO.2025.43.4_suppl.448","volume":"43","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Van Laarhoven HWM, Rha SY, et al. Updated results from the trastuzumab deruxtecan (T-DXd) 5.4\u00a0mg\/kg triplet combination of DESTINY-Gastric03 (DG-03): first-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced\/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA). J Clin Oncol. 2025;43(4suppl):448\u2013448. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.448.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1795_CR118","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1200\/JCO.2025.43.16_suppl.4059","volume":"43","author":"L Liu","year":"2025","unstructured":"Liu L, Li S, Liu Z, et al. Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC): Updated results from the RCTS trial. J Clin Oncol. 2025;43(16suppl):4059\u20134059. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4059.","journal-title":"J Clin Oncol"},{"key":"1795_CR119","unstructured":"A new claudin 18.2-targeting approach appears promising in gastric cancers. Accessed April 1, 2026. https:\/\/dailyreporter.esmo.org\/esmo-asia-congress-2025\/esmo-asia-congress\/a-new-claudin-18.2-targeting-approach-appears-promising-in-gastric-cancers"},{"key":"1795_CR120","doi-asserted-by":"publisher","first-page":"106575","DOI":"10.1016\/j.bioorg.2023.106575","volume":"137","author":"Y Li","year":"2023","unstructured":"Li Y, Si R, Wang J, et al. Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects. Bioorg Chem. 2023;137:106575. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106575.","journal-title":"Bioorg Chem"},{"issue":"9","key":"1795_CR121","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","volume":"21","author":"AT Hooper","year":"2022","unstructured":"Hooper AT, Marquette K, Chang CPB, et al. Anti-extra domain B splice variant of fibronectin antibody-drug conjugate eliminates tumors with enhanced efficacy when combined with checkpoint blockade. Mol Cancer Ther. 2022;21(9):1462\u201372. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0099.","journal-title":"Mol Cancer Ther"},{"issue":"695","key":"1795_CR122","doi-asserted-by":"publisher","first-page":"eabp9229","DOI":"10.1126\/scitranslmed.abp9229","volume":"15","author":"I Melero","year":"2023","unstructured":"Melero I, Tanos T, Bustamante M, et al. A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Sci Transl Med. 2023;15(695):eabp9229. https:\/\/doi.org\/10.1126\/scitranslmed.abp9229.","journal-title":"Sci Transl Med"},{"issue":"21","key":"1795_CR123","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.3390\/cancers17213411","volume":"17","author":"F Zhou","year":"2025","unstructured":"Zhou F, Mu G, Bi H, et al. Targeted hyaluronan degradation enhanced tumor growth inhibition in gastrointestinal cancer models. Cancers. 2025;17(21):3411. https:\/\/doi.org\/10.3390\/cancers17213411.","journal-title":"Cancers"},{"issue":"43","key":"1795_CR124","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1038\/s41388-025-03567-x","volume":"44","author":"X Wei","year":"2025","unstructured":"Wei X, Wu J, Cao W, et al. A novel FAP-targeting antibody-exatecan conjugate improves immune checkpoint blockade by reversing immunosuppressive microenvironment in pancreatic cancer. Oncogene. 2025;44(43):4114\u201329. https:\/\/doi.org\/10.1038\/s41388-025-03567-x.","journal-title":"Oncogene"},{"issue":"1","key":"1795_CR125","doi-asserted-by":"publisher","first-page":"10213","DOI":"10.1038\/s41467-024-53223-3","volume":"15","author":"S Siena","year":"2024","unstructured":"Siena S, Raghav K, Masuishi T, et al. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024;15(1):10213. https:\/\/doi.org\/10.1038\/s41467-024-53223-3.","journal-title":"Nat Commun"},{"issue":"6","key":"1795_CR126","doi-asserted-by":"publisher","first-page":"e175834","DOI":"10.1172\/JCI175834","volume":"134","author":"Z Sun","year":"2024","unstructured":"Sun Z, Zhang T, Ahmad MU, et al. Comprehensive assessment of immune context and immunotherapy response via noninvasive imaging in gastric cancer. J Clin Invest. 2024;134(6):e175834. https:\/\/doi.org\/10.1172\/JCI175834.","journal-title":"J Clin Invest"},{"issue":"3","key":"1795_CR127","doi-asserted-by":"publisher","first-page":"bbaf228","DOI":"10.1093\/bib\/bbaf228","volume":"26","author":"L Chen","year":"2025","unstructured":"Chen L, Li B, Chen Y, et al. ADCNet: a unified framework for predicting the activity of antibody-drug conjugates. Brief Bioinform. 2025;26(3):bbaf228. https:\/\/doi.org\/10.1093\/bib\/bbaf228.","journal-title":"Brief Bioinform"},{"key":"1795_CR128","doi-asserted-by":"publisher","unstructured":"Noriega HA, Wang XS. AI-driven innovation in antibody-drug conjugate design. Front Drug Discovery. 2025;5. https:\/\/doi.org\/10.3389\/fddsv.2025.1628789.","DOI":"10.3389\/fddsv.2025.1628789"},{"issue":"21","key":"1795_CR129","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.3390\/cancers17213419","volume":"17","author":"N Sobhani","year":"2025","unstructured":"Sobhani N, Kugeratski FG, Venturini S, et al. AI-based cancer models in oncology: from diagnosis to ADC drug prediction. Cancers. 2025;17(21):3419. https:\/\/doi.org\/10.3390\/cancers17213419.","journal-title":"Cancers"},{"issue":"12","key":"1795_CR130","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.tips.2025.10.005","volume":"46","author":"Y Wang","year":"2025","unstructured":"Wang Y, Guo C, Li W. Artificial intelligence in antibody-drug conjugate development. Trends Pharmacol Sci. 2025;46(12):1209\u201323. https:\/\/doi.org\/10.1016\/j.tips.2025.10.005.","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"1795_CR131","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1021\/acs.jcim.5c00037","volume":"65","author":"L Angiolini","year":"2025","unstructured":"Angiolini L, Manetti F, Spiga O, Tafi A, Visibelli A, Petricci E. Machine learning for predicting the drug-to-antibody ratio (DAR) in the synthesis of antibody-drug conjugates (ADCs). J Chem Inf Model. 2025;65(12):5847\u201355. https:\/\/doi.org\/10.1021\/acs.jcim.5c00037.","journal-title":"J Chem Inf Model"},{"issue":"1","key":"1795_CR132","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12885-024-12174-0","volume":"24","author":"PC Zhan","year":"2024","unstructured":"Zhan PC, Yang S, Liu X, et al. A radiomics signature derived from CT imaging to predict MSI status and immunotherapy outcomes in gastric cancer: A multi-cohort study. BMC Cancer. 2024;24(1):404. https:\/\/doi.org\/10.1186\/s12885-024-12174-0.","journal-title":"BMC Cancer"},{"key":"1795_CR133","doi-asserted-by":"publisher","unstructured":"Liu Z, Li X, Huang Y, et al. CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma cases: a multi-center study. Hepatol Int Published online July. 2025;23. https:\/\/doi.org\/10.1007\/s12072-025-10877-5.","DOI":"10.1007\/s12072-025-10877-5"},{"issue":"3","key":"1795_CR134","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s10120-025-01584-z","volume":"28","author":"P Zhang","year":"2025","unstructured":"Zhang P, Tao C, Xie H, et al. Identification of CD66c as a potential target in gastroesophageal junction cancer for antibody-drug conjugate development. Gastric Cancer: Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2025;28(3):422\u201341. https:\/\/doi.org\/10.1007\/s10120-025-01584-z.","journal-title":"Gastric Cancer: Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"11","key":"1795_CR135","doi-asserted-by":"publisher","first-page":"e1480","DOI":"10.1093\/oncolo\/oyae168","volume":"29","author":"D Morgenstern-Kaplan","year":"2024","unstructured":"Morgenstern-Kaplan D, Kareff SA, Trabolsi A, et al. Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. Oncologist. 2024;29(11):e1480\u201391. https:\/\/doi.org\/10.1093\/oncolo\/oyae168.","journal-title":"Oncologist"},{"issue":"1","key":"1795_CR136","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","volume":"13","author":"J Qi","year":"2022","unstructured":"Qi J, Sun H, Zhang Y, et al. Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1\u2009+\u2009macrophages in colorectal cancer. Nat Commun. 2022;13(1):1742. https:\/\/doi.org\/10.1038\/s41467-022-29366-6.","journal-title":"Nat Commun"},{"issue":"2","key":"1795_CR137","doi-asserted-by":"publisher","first-page":"907","DOI":"10.18632\/aging.203850","volume":"14","author":"Z Liang","year":"2022","unstructured":"Liang Z, Huang A, Wang L, et al. A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment. Aging (Milano). 2022;14(2):907\u201322. https:\/\/doi.org\/10.18632\/aging.203850.","journal-title":"Aging (Milano)"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01795-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01795-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01795-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:48:18Z","timestamp":1779209298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01795-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":137,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1795"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01795-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}